|
|
Blood, 15 July 2005, Vol. 106, No. 2, pp. 401-407.
Prepublished online as a Blood First Edition Paper on April 5, 2005; DOI 10.1182/blood-2005-02-0626.
 Previous Article | Next Article 
Submitted February 14, 2005
Accepted March 1, 2005
Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy
Ian A Greer* and Catherine Nelson-Piercy
University of Glasgow, Glasgow, Scotland
Guy's & St Thomas' Hospitals Trust & Queen Charlotte's Hospital, London, United Kingdom
* Corresponding author; email: I.A.Greer{at}clinmed.gla.ac.uk.
To assess the safety and efficacy of low-molecular-weight heparins (LMWHs) for thromboprophylaxis and treatment of venous thromboembolism (VTE) in pregnancy, a systematic review of studies to the end of 2003 was undertaken. Data on VTE recurrence and side effects were extracted and cumulative incidences of VTE and adverse effects calculated.
Of 81 reports identified, 64 reporting 2777 pregnancies were included. In 15 studies (174 patients) the indication for LMWH was treatment of acute VTE and in 61 studies (2603 pregnancies) it was thromboprophylaxis or adverse pregnancy outcome. There were no maternal deaths. VTE and arterial thrombosis (associated with antiphospholipid syndrome) were reported in 0.86% (95% confidence interval [CI] 0.55-1.28) and 0.50% (95% CI 0.28-0.84) of pregnancies, respectively. Significant bleeding, generally associated with primary obstetric causes, occurred in 1.98% (95% CI 1.50-2.57), allergic skin reactions in 1.80% [95% CI 1.34-2.37], heparin-induced thrombocytopenia in 0%, thrombocytopenia (unrelated to LMWH) in 0.11% (95% CI 0.02-0.32), and osteoporotic fracture in 0.04% (1) (95% CI <0.01-0.20) of pregnancies. Overall, live births were reported in 94.7% of pregnancies, including 85.4% in those receiving LMWH for recurrent pregnancy loss.
LMWH is both safe and effective to prevent or treat VTE in pregnancy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Quinn, K. Von Klemperer, R. Brooks, D. Peebles, F. Walker, and H. Cohen
Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience
Haematologica,
November 1, 2009;
94(11):
1608 - 1612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Martineau and C Nelson-Piercy
Venous thromoboembolic disease and pregnancy
Postgrad. Med. J.,
September 1, 2009;
85(1007):
489 - 494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Urman, B. Ata, K. Yakin, C. Alatas, S. Aksoy, R. Mercan, and B. Balaban
Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial
Hum. Reprod.,
July 1, 2009;
24(7):
1640 - 1647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. James
Venous Thromboembolism in Pregnancy
Arterioscler Thromb Vasc Biol,
March 1, 2009;
29(3):
326 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. GIBSON and R. POWRIE
Anticoagulants and pregnancy: When are they safe?
Cleveland Clinic Journal of Medicine,
February 1, 2009;
76(2):
113 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Marik and L. A. Plante
Venous Thromboembolic Disease and Pregnancy
N. Engl. J. Med.,
November 6, 2008;
359(19):
2025 - 2033.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Nelson and I. A. Greer
The potential role of heparin in assisted conception
Hum. Reprod. Update,
November 1, 2008;
14(6):
623 - 645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
340S - 380S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Bates, I. A. Greer, I. Pabinger, S. Sofaer, and J. Hirsh
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
844S - 886S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C A Davie and P O'Brien
Stroke and pregnancy
J. Neurol. Neurosurg. Psychiatry,
March 1, 2008;
79(3):
240 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Spyropoulos
Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2008;
14(1):
63 - 74.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. M. Bates
Management of Pregnant Women with Thrombophilia or a History of Venous Thromboembolism
Hematology,
January 1, 2007;
2007(1):
143 - 150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The ESHRE Capri Workshop Group
Hormones and cardiovascular health in women
Hum. Reprod. Update,
September 1, 2006;
12(5):
483 - 497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jauniaux, R. G. Farquharson, O. B. Christiansen, N. Exalto, and On behalf of ESHRE Special Interest Group for Earl
Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage
Hum. Reprod.,
September 1, 2006;
21(9):
2216 - 2222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Arepally and T. L. Ortel
Heparin-Induced Thrombocytopenia
N. Engl. J. Med.,
August 24, 2006;
355(8):
809 - 817.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Wiles and B J Hunt
Anticoagulation via anti-Factor Xa inhibition
Lupus,
March 1, 2006;
15(3):
167 - 171.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher
Unfractionated LMWH and the risk of HIT: are medical patients different?
Blood,
November 1, 2005;
106(9):
2931 - 2932.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Prandoni, S. Siragusa, B. Girolami, F. Fabris, and for the BELZONI Investigators Group
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study
Blood,
November 1, 2005;
106(9):
3049 - 3054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
